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Cytochrome P450s metabolize the naturally occurring
nephrotoxin aristolochic acid. Using liver-specific cytochrome
P450 reductase-null mice we found that a low but lethal dose
of aristolochic acid I was ineffective in wild-type mice.
Induction of hepatic CYP1A by 3-methylcholanthrene
pretreatment markedly increased the survival rate of wild
type mice given higher doses and these mice were protected
from aristolochic acid I-induced renal injury. Clearance of
aristolochic acid I in null mice was slower compared to
control and the 3-methylcholanthrene-pretreated wild type
mice. The levels of aristolochic acid I in the kidney and liver
were much higher in null mice but much lower in 3-
methylcholanthrene-treated compared to control wild type
mice. Hepatic microsomes from 3-methylcholanthrene-
treated wild type mice had greater activity compared to
untreated mice. Finally, aristolochic acid I was more cytotoxic
than its major metabolite aristolactam I and this cytotoxicity
was decreased in human renal tubular epithelial HK2 cells in
the presence of a reconstituted hepatic microsome-cytosol
(S9) system. These results indicate that hepatic P450s play an
important role in metabolizing aristolochic acid I into less
toxic metabolites and thus have a detoxification role in
aristolochic acid I-induced kidney injury.
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A rapidly progressive interstitial nephropathy, originally
called Chinese herb nephropathy and now known as
aristolochic acid nephropathy (AAN), was first reported in
a weight-loss program in Belgium during the early 1990s,
from which nearly 50% of patients needed renal replacement
therapy.1 Since then, many cases of AAN have been reported
worldwide.2,3 The characteristic of AAN is very similar to
that of Balkan endemic nephropathy (BEN), characterized by
its invariable progression to chronic renal failure and a strong
association with urothelial carcinoma of the upper urinary
tract.4,5 Aristolochic acid (AA) was proven to be the cause of
AAN1,6 and possibly a risk factor for the development of
BEN.7
AA is the active principle extracted from Aristolochia
species, consisting of a mixture of structurally related
nitrophenanthrene derivatives8 AA I is the most toxic and
carcinogenic compound.9,10 The metabolism studies of AA in
various species showed that aristolactams (AL) are the major
metabolites in urine and feces11 AA activation was attributed
primarily to CYP1A1/2 in human hepatic microsomes, in
which CYP1A2 was the major contributor, whereas NADPH
P450 reductase (CPR) was shown to play a minor role.12,13
CPR and prostaglandin H synthase (PHS/COX) are more
effective in human renal microsomes,14 and NAD(P)H:
quinine oxidoreductase (NQO1) is the most efficient
cytosolic reductase in human liver and kidney in AA
activation.15 However, these findings came from in vitro
studies and the metabolites were identified only in excreta;
the in vivo fate of AA is still unknown. It is possible that both
microsomal and cytosolic enzymes in the liver and kidney
may have the ability to metabolize AA in vivo. However,
whether AA-induced kidney injury requires hepatic micro-
somal biotransformation of AA remains to be determined.
The cytochrome P450s are the most important xenobio-
tic-metabolizing enzymes participating in the metabolism of
most foreign chemicals.16 Besides the abundant P450s in
the liver, various extrahepatic P450s also contribute to the
xenobiotic biotransformation. It remains unclear whether
liver-generated AA metabolites can be transported to
the kidney through systemic circulation and contribute
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to the kidney toxicity directly or via further metabolism in
the kidney. A unique mouse model named liver-Cpr-null or
HRN mice (Null) has been developed recently,17,18 in which
the Cpr gene encoding for the obligate redox partner for all
microsomal P450s is deleted specifically in the liver, resulting
in the loss of B95% of hepatic microsomal activity.17
Recently, this model has been used in a number of
studies.19–22 For the first time, we use this novel mouse
model to study AA-induced kidney toxicity.
This study aims to determine whether hepatic P450-
dependent metabolism is required in the AAI-induced renal
toxicity. We designed a loss-of-function experiment using the
Null mice and a gain-of-function experiment using wild-type
(WT) mice pretreated with the CYP1A inducer 3-methyl-
cholanthrene (MC)23 to identify the role of hepatic P450s in
the metabolism of AAI and resultant toxicity in the kidney.
Here, we provide the first evidence that hepatic P450s
(especially CYP1A) contribute to AAI clearance in vivo, and
these enzymes may play a detoxification role in AAI-induced
kidney toxicity by metabolizing AAI into less toxic
metabolites.
RESULTS
Survival rate in Null, WT, and MC-WT mice after AAI
treatment
The survival rate was determined in Null, WT, and MC-
pretreated WT (MC-WT) mice within 14 days after AAI
treatment to find the difference in the susceptibility to AAI
toxicity. After a single intraperitoneal injection of AAI at 10
or 20 mg kg1, no death was observed in the WT mice,
whereas in Null mice treated with 10 and 20 mg kg1 AAI, a
survival rate of 70 and 10%, respectively, was observed,
(Figure 1a and b). At 30 mg kg1 AAI, all of the WT mice
were dead after 8 days, whereas most of the MC-WT mice
survived within 14 days after the treatment (Figure 1c). These
results suggested that inactivation of hepatic CPR and P450s
has an enhancing effect on AAI-induced toxicity, whereas
induction of CYP1A by MC in the liver has a protective effect
on the AAI toxicity.
Comparison of AAI-induced kidney toxicity among Null, WT,
and MC-WT mice
The in vivo toxicity of AAI was further examined in Null, WT,
and MC-WT mice 14 days after treatment with AAI at
10 mg kg1. In AAI-treated groups, the body weight of Null
mice started to decline on the 4th day after the injection
(Figure 2a), whereas there was a slight decline in WT mice
starting on the 8th day after the injection (Figure 2b), and
MC-WT mice showed no significant weight loss (Figure 2c).
Histologically, severe atrophy of the proximal tubular
population, tubulointerstitial lesions, hyperplasia, and ex-
tensive interstitial fibrosis were observed in the kidney of Null
mice (Figure 2d), whereas there was a lesser extent of these
lesions observed in WT mice (Figure 2e), and the fibrosis was
strikingly decreased in MC-WT mice along with loss of
tubular epithelia and slight interstitial hyperplasia in the
kidney (Figure 2f). The severity of lesions in the kidney was
graded among the three groups of mice (Table 1). The gross
morphology of the kidneys of Null mice was pale in color
compared with the kidneys of WT mice (Figure 2g). Serum
BUN (blood urea nitrogen) and creatinine levels increased
markedly in Null and WT mice compared with the control
groups (Figure 2h and i), but the extent of the increase was
greater in Null mice than that in WT mice. However, in MC-
WT mice, the levels remained unchanged compared with the
control WT group. These findings suggested that the
inactivation of hepatic CPR and P450 activities in Null mice
resulted in a greater sensitivity toward AAI-induced renal
injury that and the pretreatment of MC can protect the mice
from renal injury induced by AAI.
AAI clearance in Null, WT, and MC-WT mice
The contribution of hepatic P450s to AAI metabolism was
determined in vivo by comparing the blood levels of AAI
among the Null, WT, and MC-WT mice after a single
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Figure 1 | Survival rate in the WT, Null, and MC-pretreated
wild-type (MC-WT) mice. Two-month-old male WT, Null, and
MC-WT mice were observed for mortality within 14 days after a
single injection of AAI at various doses. (a) 10 mg kg1 AAI, n¼ 10
in each group, (b) 20 mg kg1 AAI, n¼ 8 in each group,
(c) 30 mg kg1 AAI, n¼ 8 in each group, the MC-WT group was
pretreated with 60 mg kg1 MC 24 h before the AAI injection.
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intraperitoneal injection of AAI at 10 or 20 mg kg1. The
clearance of AAI in Null mice was much slower than that in
WT mice, whereas the clearance was faster in MC-WT mice
compared with WT mice after the treatment at both AAI
doses (Figure 3a and b). Noticeably, the blood AAI levels
started to decrease in MC-WT mice 5 min after the dosing,
whereas the levels in Null mice started to decline atB30 min
after the injection, and the blood concentration still remained
about 30% of the peak levels in Null mice at 60 min. These
findings suggested that the inactivation of hepatic CPR and
P450 activities in Null mice greatly compromised the
metabolic capacity to activate AAI, whereas the induction
of hepatic CYP1A enhanced the clearance of AAI in the WT
mice.
The levels of AAI and its metabolites in the liver and kidney
of Null, WT, and MC-WT mice
The levels of AAI and its major metabolites AAIa and ALI in
the liver and kidney were also determined in Null, WT, and
MC-WT mice at 30 min after injection of AAI at 10 or
20 mg kg1 using authentic standard and LC-MS/MS
(liquid chromatography-mass spectrometry and liquid chro-
matography-tandem mass spectrometry) analysis. Represen-
tative HPLC (high-performance liquid chromatography)
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Figure 2 | Comparison of AAI-induced kidney toxicity in the Null, WT, and MC-WT mice. All mice received a single intraperitoneal
injection of AAI at 10 mg kg1. (a–c) Body weight during 14 days after the treatment. Values presented are mean±s.d., n¼ 5. **Po0.01
versus control mice. Histological examination of the kidney in AAI-treated Null (d), WT (e), and MC-WT (f) mice at 14 days (h and e stain,
original magnifications  200). (g) Representative kidney gross morphology in WT and Null mice at 14 days after the AAI treatment.
(h) Serum BUN and (i) creatinine at 14 days. Values presented are mean±s.d., n¼ 5. **Po0.01 versus control mice. ##Po0.01 versus
WT mice.
Table 1 | Extent of kidney injury in the Null, WT, and MC-WT
mice
Number of mice in each grade
Time AA dose Group + ++ +++
3 days 20 mg kg1 Null 0 0 5
WT 1 4 0
14 days 10 mg kg1 Null 0 0 5
WT 0 4 1
MC-WT 5 0 0
AA, aristolochic acid; MC-WT, 3-methylcholanthrene-treated WT mice; WT, wild type.
Two-month-old male mice were treated with a single intraperitoneal injection of AAI
at 10 or 20 mg kg1. Histopathology of the kidneys was examined at 3 or 14 days
after the treatment. The severity of lesions in the tissues was graded as: +, mild; ++,
moderate; +++, severe.
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chromatograms from the liver and kidney of the 20 mg kg1
AAI group are shown in Figure 4a and e. The levels of AAI in
the liver and kidney were found to be the highest in Null
mice (Figure 4b and f) and the lowest in MC-WT mice
among the three groups of mice at both AAI doses, which is
consistent with the AAI levels in the blood in the three
groups. The AAIa levels were found to be the lowest in the
liver (Figure 4c) and kidney (Figure 4g) of Null mice, and
ALI levels were found to be the highest in these two organs of
Null mice among the three groups at both doses, whereas ALI
levels were below the detection limit in the liver of WT and
MC-WT mice (Figure 4d and h). These results suggested that
the metabolism of AAI was suppressed in the liver of Null
mice, leading to altered levels of AAI metabolites; conversely,
the induction of hepatic CYP1A enhanced the elimination of
AAI in the liver and kidney.
In vitro metabolism of AAI in liver microsomes from the liver
of Null, WT, and MC-WT mice
The in vitro metabolism of AAI in the hepatic microsomes
was determined in Null, WT, and MC-WT mice. Representa-
tive HPLC chromatograms are shown in Figure 5a. After
incubation, the relative AAI concentration in microsomes
from Null mice remained approximately 100% of the initial
concentration, whereas in microsomes from WT and
MC-WT mice, the final AAI concentration decreased to
about 89 and 73%, respectively, of the initial concentrations
(Figure 5b). Furthermore, AAIa was detected, but not ALI,
under this incubation condition. The level of AAIa was
markedly increased in microsomes from MC-WT mice and
was significantly lower in microsomes from Null mice than
that from WT mice (Figure 5c). Western blot analysis
revealed that the protein level of CYP1A2 was greatly
increased in MC-WT mice compared with WT mice, along
with a slight increase in CPR in the liver. However, the
expression of CYP1A2 and CPR in the kidney remained
unchanged in the MC-treated mice compared to Null and
WT mice (Figure 5d). CYP1A1 and 1A2 activities were also
determined by using EROD (7-ethoxyresorufin O-deethyla-
tion) and MROD (7-methoxyresorufin O-demethylation)
assays. The levels of CYP1A1 (Figure 5e) and 1A2 activities
(Figure 5f) in the hepatic microsomes from MC-WT mice
were B30- and B10-fold, respectively, higher than those in
the control mice. However, renal CYP1A1 and 1A2 activities
remained unchanged compared to the control mice and were
strikingly lower than those in the liver. These results pointed
to a notion that MC treatment facilitated the clearance of
AAI from the body via induction of hepatic CYP1A and CPR;
additionally, hepatic P450s are responsible for metabolizing
AAI, and CYP1A seems to play a significant role in the
formation of AAIa.
Cytotoxicity of AAI and ALI, and the effect of liver S9 fraction
on AAI cytotoxicity
To support the notion that high levels of AAI accumulated in
the kidney correlated with the increased renal toxicity in the
Null mice and that ALI contributed little to the in vivo
toxicity, we compared the cytotoxicity of AAI and ALI in a
human proximal tubular cell line HK2. At the concentration
of 25, 50, and 100 mM, AAI exhibited a higher inhibition rate
of cell viability than ALI (Figure 6a); however, the inhibition
effect of AAI was almost equivalent to that of ALI at the same
molar concentration in the presence of S9 fraction from the
liver of MC-WT mice (Figure 6b). These results demon-
strated that AAI is more cytotoxic than ALI in HK2 cells,
suggesting that the increased AAI-induced renal toxicity in
Null mice is due to a greater accumulation of AAI in the
kidney and that a high concentration of AAI can result in
renal toxicity directly or via further metabolism to toxic
metabolites by other renal biotransformation enzymes.
DISCUSSION
AA ingestion is responsible for AAN and possibly a cause for
BEN.7,24 Despite numerous investigations on the possible
involvement of P450s and other enzymes in the metabolic
activation of AA, the role of hepatic P450s in the metabolism
of AA and resultant renal toxicity has not been examined. By
using the liver-Cpr-null mice,17,18 it is possible to directly
determine the in vivo contributions of CPR and hepatic P450
enzymes to the disposition and toxicity of AA. We reported
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Figure 3 | The serum levels of AAI in the Null, WT, and MC-WT
mice. Two-month-old male mice received a single intraperitoneal
injection of AAI at 10 mg kg1 (a) and 20 mg kg1 (b). Tail blood
samples were collected from individual mice at nine time points
after dosing, for determination of AAI concentrations, as
described in Materials and Methods. Values presented are
mean±s.d. n¼ 6 for Null and WT mice, n¼ 5 for MC-WT mice.
**Po0.01 versus WT mice.
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the HPLC chromatogram. Values presented are mean±s.d. n¼ 4, **Po0.01 versus WT mice. ND, not detected.
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here, for the first time, that the hepatic P450s play a critical
role in detoxification of the AAI-induced kidney injury and
demonstrated in vivo that hepatic P450s are involved in the
clearance of AAI. Moreover, it appeared that the AAI-induced
renal injury does not require hepatic P450/CPR-dependent
metabolic activation of AAI.
CYP1A, the major subfamily of hepatic P450 enzymes
responsible for the activation of AA in vitro,13,25 is normally
expressed at a low level. The WT mice pretreated with MC
were used as a gain-of-function model for CYP1A in the liver
in comparison with Null mice, as the induction of CYP1A by
MC was rapid and tissue-specific23,26 in the liver with a
substantial increase in the metabolic activities to CYP1A
substrates. The induction of CYP1A by MC greatly enhanced
the clearance of AAI in the blood, liver, and kidney. As a
result, the MC-treated mice were resistant to doses that were
lethal to WT mice and exhibited a lesser extent of AAI-
induced toxicity in the kidney. These findings are consistent
with the previous reports that CYP1A is the major enzyme
responsible for the metabolic activation of AA.12,13,25
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A marked increase in the production of AAIa in the hepatic
microsomes from MC-WT mice further supports the notion
that hepatic CYP1A contributed significantly to the meta-
bolism of AAI. It appears that hepatic CYP1A may play an
important role in the oxidation of AAI to AAIa, a suggested
detoxification pathway that was inactivated in the liver of
Null mice and enhanced in MC-WT mice. AAIa can be
quickly conjugated by phase II enzymes and readily
eliminated from the body.27 This may explain why there
was no difference in the level of AAIa between the MC-WT
and WT mice in vivo. AAIa can be further metabolized into
ALIa,28 which is then excreted, and becomes the principal
metabolite of AAI detected in urine and feces in rats.11 The
relative role of renal P450s in AA-induced renal toxicity
in vivo is unclear. The renal CYP1A activities remained
similar among the Null, WT, and MC-WT mice, and the level
of CYP1A in the kidney is much lower than that in the liver
in WT mice, indicating that the renal P450s might play a less
important role in metabolizing AAI.
Unexpectedly, a high level of ALI was found in the liver of
the Null mice, whereas its level was much lower or
undetectable in WT and MC-WT mice. Previous in vitro
studies have demonstrated that other non-P450 enzymes
were also involved in the metabolism of AA, including
hepatic and renal NQO1, renal CPR, and PHS/COX.13,15
In the liver of Null mice, the formation of ALI may be
catalyzed by these enzymes owing to the high level of AAI in
the liver. Alternatively, there might be a compensatory
induction of these enzymes in the liver, in response to the
loss of CPR, along with an induction of other biotransforma-
tion enzymes observed in the liver of the Null mice.29 The
higher ALI level found in the kidney of the Null mice could
be due to the increased production of ALI by renal enzymes
owing to an increased availability of AAI in the kidney.
Previous in vitro cytotoxic studies revealed that AAI is more
cytotoxic than its major metabolite AAIa and ALI,9,30 which
was confirmed in our experiments.
The mechanism of acute renal injury in mice induced by a
single injection of a high dose of AAI might be different from
the chronic kidney failure via a long-term ingestion of AA at
lower levels. It is suggested that AA may directly cause acute
renal toxicity and apoptosis through regulating mito-
chondrial transition permeability in HK2 cells.31 Reactive
intermediates of AA formed by non-P450/CPR enzymes in
the kidney could play a more important role in carcino-
genesis through AA-DNA adduct formation. Other enzymes
that are known to be active toward AA, such as NQO1 and
COX, are expressed at high levels in the urothelial tissue and
kidney.14 The AA-DNA adducts were detected in both kidney
and liver,32 whereas AA-induced carcinogenesis occurs only
in the kidney; whether renal P450s or other renal biotrans-
formation enzymes are involved in the tissue-specific tumor
formation is still unknown. A case report that AA-related
urinary tract cancer occurred without significant renal injury
may suggest a possible dissociation in the mechanisms
between carcinogenicity and nephrotoxicity of AA.33
Identifying the P450 isoforms that are involved in the
metabolic activation/detoxification of AAI in mice will
provide an insight into the relationship between polymorph-
ism of the P450 isoforms and susceptibility to AA-induced
toxicity in humans. Our findings that CYP1A played an
important role in the metabolism of AAI in vivo are
consistent with the previous in vitro findings that CYP1A,
especially 1A2, contributes significantly to AA metabolism.12
Genetic polymorphisms of CYP1A were reported in
humans,34,35 suggesting that populations with lower expres-
sion of CYP1A may have a higher risk for AAN and BEN.
In conclusion, hepatic P450/CPR plays a detoxification
role in the AAI-induced renal injury through the metabolism
of AAI into less toxic metabolites in the liver, and hepatic
CYP1A is an important isoform involved in the metabolism
of AAI in mice in vivo. Our findings provide new insights
into the mechanism of AA-induced nephrotoxicity and
possible new approaches to the intervention/prevention of
AAN and BEN.
MATERIALS AND METHODS
Animal treatment
Liver-specific Cpr-null (Null) mice were a gift from Dr Xinxin Ding
(Wadsworth Center, Albany, NY, USA). Protocols for
animal breeding and genotyping were reported previously.36
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Figure 6 | In vitro cytotoxicity assay for determining the toxic
potency of AAI and ALI in human renal tubular epithelial cells
(HK2). (a) Cell viability was determined in HK2 cells at 24 h after
the treatment with AAI and ALI at concentrations of 25, 50, and
100mM. **Po0.01 versus ALI-treated group. (b) The effect of S9
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The results are representative of three individual experiments.
Kidney International (2008) 73, 1231–1239 1237
Y Xiao et al.: Detoxification role of liver P450s in AA toxicity o r i g i n a l a r t i c l e
Two-month-old male mice from Null and WT littermate groups on
mixed C57BL/6 and 129/Sv genetic background were used in the
studies. Animal use protocols were approved by the Institutional
Animal Care and Use Committee of the Shanghai Institute of
Materia Medica, China. For survival experiments, mice were
administered a single intraperitoneal injection of AAI (Sigma
Chemical Co., St Louis, MO, USA) in saline at either doses of 10,
20, and 30 mg kg1, and the number of surviving animals was
recorded within 14 days after the treatment. MC (Fluka Chemie AG,
Buchs, Switzerland) pretreated WT mice were treated with a single
intraperitoneal injection of MC at 60 mg kg1 in corn oil 24 h before
AAI injection. For toxicokinetics and toxicity experiments, mice
were treated with a single intraperitoneal injection of AAI at a dose
of 10 or 20 mg kg1. Animals in the control groups received the
vehicle only.
Histopathological examination
Mice were killed by CO2 overdose at 14 days after AAI injection.
Kidneys were collected and processed according to a standard
pathology procedure.17 Sections at 3–4 mM were stained with
hematoxylin and eosin.
Determination of serum BUN and creatinine
Serum creatinine and BUN levels were determined by an L-Type
Creatinine F kit and an L-Type UN kit using a Hitachi-7080
biochemical analyzer.
Determination of the levels of AAI and metabolites in blood,
liver, and kidney
For the determination of AAI concentrations, blood samples were
collected by tail bleeding at various time points after the injection.
Blood samples (15 ml each) were collected in heparin-coated
capillaries and were mixed with an equal volume of saline. The
samples were spun at 4000 g for 5 min at 4 1C. Tissue samples were
homogenized in saline, the supernatant was removed and spun at
14 000 g for 10 min, and then the supernatants were mixed with one-
half volume of methanol and spun again at 14 000 g for 5 min to
remove precipitated proteins. Aliquots of the final supernatants were
analyzed and quantified for the levels of AAI and the metabolites
AAIa and ALI by a HPLC with confirmation by LC-MS/MS as
described below. The identity of AAIa and ALI was confirmed with
synthesized standards provided by Dr Minghua Xu (Shanghai
Institute of Materia Medica).
HPLC/UV and LC-MS/MS analysis of AAI and its metabolites
The quantification of AAI and its metabolites in the samples was
performed on an HP1100 HPLC system equipped with an
autosampler (Agilent Technologies, Palo Alto, CA, USA) as
described.37 The detection conditions were set to 70% absolute
methanol and 30% acetic acid (0.1% in H2O), 0.8 ml min
1, UV
250 nm. In addition, LC-MS/MS analyses were conducted on an
Agilent 6300 LC/MSD Trap XCT Ultra (Agilent Technologies
Deutschland GmbH, Waldbronn, Germany) as described by Yuan
et al.38 to confirm and characterize the metabolites. The electrospray
ionization source was operated in positive ion mode. The MSn
product-ion spectra were produced by collision-induced dissocia-
tion of the molecular ion [MþH]þ of all analytes at their
respective HPLC retention times. Data acquisition was performed in
full-scan MS and MS(n) modes.
In vitro AAI metabolism in hepatic microsomes
Incubations were carried out at 37 1C for 2 h in a tube containing
20 mg ml1 AAI dissolved in 25 ml dimethyl sulfoxide, 1 mg ml1
microsomal protein, and an NADPH-generating system (5 mM
glucose-6-phosphate, 3 mM MgCl2, 1 mM NADP
þ, and 1.5 units of
glucose-6-phosphate dehydrogenase) in 100 mM sodium phosphate,
pH 7.4, in a total volume of 250 ml. The reaction was initiated by the
addition of the NADPH-generating system and stopped by addition
of 125 ml ice-cold acetonitrile. The precipitate was removed by
centrifugation at 14 000 g for 10 min. The levels of AAI and its
major metabolite AAIa were determined by the HPLC method
described above.
In vitro AAI toxicity in human renal tubular epithelial cell line
(HK2)
HK2 cells (ATCC (American Type Culture Collection), Manassas,
VA, USA) were grown in keratinocyte serum-free medium
(Life Technologies, Grand Island, NY, USA), according to the
culture instruction from ATCC, and were maintained at 37 1C in a
humidified incubator with 95% air and 5% CO2 during the
experiment. The cells were treated with AAI and ALI at 25, 50, and
100 mM for 24 h before the measurement of cell viability. The hepatic
S9 fraction was diluted to the desired concentration (1 mg ml1) in
the medium containing 1.4 mg ml1 glucose, 3 mg ml1 co-enzyme
II, 5 mM MgCl2, 33 mM KCl. The cells were incubated with the above
medium with or without AAI at 50 mM for 2 h, followed by
replacement with fresh normal medium for another 22 h before the
measurement of cell viability. The cell viabilities were measured by a
Cell counting kit-8 (Dojindo, Kumamoto, Japan) according to the
manufacturer’s instructions.
Other methods
Microsomes and S9 fractions were prepared from the liver
and kidney according to a standard protocol.39 Protein concentra-
tions were determined using a BCATM protein assay kit
(Pierce, Rockford, IL, USA). The O-dealkylase activity was
determined by the formation of EROD and MROD as described
by Burke et al.39 In western blot analysis, the expression of
CYP1A, CPR, and GAPDH was determined in microsome samples
from the liver and kidney using an ECL system (Amersham,
Piscataway, NJ, USA), as described previously31 with the following
antibodies: monoclonal rabbit anti-mouse GAPDH (1:1000; Cell
Signaling Technology, Danvers, MA, USA), polyclonal rabbit anti-
mouse cytochrome P450 reductase (1:1000; Abcam, Cambridge,
UK), or sheep anti-rat CYP1A2 (1:1000; Chemicon, Temecula, CA,
USA) antibody. One-way analysis of variance and Student’s t-test
were used for statistical analysis, with Po0.05 accepted as
significant.
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